Jazz Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Jazz Pharmaceuticals plc
PredecessorJazz Pharmaceuticals, Inc. (before the 2012 tax inversion to Ireland)
FoundedMarch 2005; 14 years ago (2005-03) in Dublin, Ireland
HeadquartersWaterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland
Area served
Key people
Bruce C. Cozadd, Chairman & CEO
ProductsPharmaceutical drugs
RevenueIncrease US$1.618 billion (2017)[1]
Decrease US$528.8 million (2017)[1]
Increase US$487.8 million (2017)[1]
Total assetsIncrease US$5.123 billion (2017)[1]
Total equityIncrease US$2.713 billion (2017)[1]
Number of employees
~1,210 (February 2018)[1]

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1]

In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.[3]

The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

Company history & Acquisitions[edit]


On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia.[5] In the following December, a new patent was issued for Sodium Oxybate.[6]


On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.[7]


On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments).[8] In September the company successfully sold its Women's Health business to Meda for $95 million.[9] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.[10]


In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.[11][12]


In May, the company announced it would acquire Alizé Pharma II for $20.5 million.[13] At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion.[14] As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.[15]

Acquisition history[edit]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Jazz Pharmaceuticals
(Merged 2011)

Jazz Pharmaceuticals

Azur Pharma PLC

EUSA Pharma
(Acq 2012)

Gentium SpA
(Acq 2014)

Alizé Pharma II
(Acq 2016)

Celator Pharmaceuticals
(Acq 2016)


  1. ^ a b c d e f g "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018.
  2. ^ "History". Jazz Pharmaceuticals. Retrieved 22 November 2016.
  3. ^ "Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in "Off-label" Marketing Investigation".
  4. ^ http://www.fiercepharma.com/pharma/teva-wins-controversial-phrma-bid-despite-protests-from-branded-rivals
  5. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  6. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  7. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  8. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  9. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  10. ^ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  11. ^ Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
  12. ^ "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News (paper)|format= requires |url= (help). 34 (2). January 15, 2014. p. 10.
  13. ^ "Alizé Pharma II Acquired by Jazz Pharmaceuticals for Up to $20.5M - GEN News Highlights - GEN".
  14. ^ "Jazz Pharmaceuticals to Acquire Celator for $1.5B - GEN News Highlights - GEN".
  15. ^ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.